Nanotechnology-based Strategies in Breast Cancer Diagnosis and Therapy (IMAGE)
Caption
Nanotechnologies, nanocarriers, and nano-encapsulations versus their corresponding conventional counterparts for BCA diagnosis and therapy have been discussed. Studies conducted in vitro and in vivo have demonstrated that diagnosis and treatment using nanotechnologies, NMs, nanocarriers, and nano-encapsulation techniques were more effective than traditional technologies and bulk materials. The DD targeting BCA cells and the release of medications within the cancer cells can be substantially enhanced by reducing drug particle size. The anticancer efficacy of the free form of drugs was improved by their encapsulation in nanocarriers. The kinetic release of drugs to cancer cells over a longer duration compared to conventional technology resulted in superior efficacy. Various formulations of drugs into different nanocarriers [lipid NPs, NEs, polymeric NPs, polymer-lipid hybrid NPs, and metal-based (Au, Ag, Cu, Fe) NPs] enhanced their bioavailability and efficiency, overcoming the obstacles presented by their conventional forms. Clinical specialists have achieved enhanced outcomes in detection and monitoring of BCA at various stages using nanotechnology and nanocarriers, ultimately leading to an improved quality of life for patients and more effective prolongation of patient survival. Based on in vitro and in vivo experimental results reported in this study, evidence suggests that TNBCA is more aggressive than other subtypes of BCA and occurs mostly in young women. Nanotechnology and nanocarriers are promising strategies for treating TNBCA using various therapies.
Credit
Mohammad Reza Kasaai
Usage Restrictions
Credit must be given to the creator. Only noncommercial uses of the work are permitted.
License
CC BY-NC